Shots:
- SOPHiA GENETICS has entered a global collaboration with AstraZeneca to develop, validate, & commercialize two companion diagnostics (CDx) supporting precision oncology therapies
- The multi-year collaboration will leverage SOPHiA’s decentralized clinical trial assays & CDx capabilities to advance development & commercialization of the CDx programs
- As per the deal, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized CDx, and develop & validate its Hematological Oncology application to support a CDx program for patients with blood cancers
Ref: PRnewswire | Image: SOPHiA GENETICS & AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
